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Background: Acute myeloid leukemia (AML) and other aggressive refractory hematological malignancies
unresponsive to upfront therapy remain difficult conditions to treat. Often, the focus of therapy is centered on
achieving complete remission of disease in order to proceed with a consolidative stem cell transplant. At issue with
this paradigm is the multitude of patients who are unable to achieve complete remission with standard
chemotherapeutic options. A major benefit of transplantation is the graft versus tumor effect that follows successful
engraftment. However, with this graft versus tumor effect comes the risk of graft versus host disease. Therefore,
alternative treatment options that utilize immunotherapy while minimizing toxicity are warranted. Herein, we
propose a novel treatment protocol in which haploidentical peripheral blood stem cells are infused into patients
with refractory hematological malignancies. The end goal of cellular therapy is not engraftment but instead is the
purposeful rejection of donor cells so as to elicit a potent immune reaction that appears to break host tumor
tolerance.
Methods/design: The trial is a FDA and institutional Rhode Island Hospital/The Miriam Hospital IRB approved Phase
I/II study to determine the efficacy and safety of haploidentical peripheral blood cell infusions into patients with
refractory hematological malignancies. The primary objective is the overall response rate while secondary objectives
will assess the degree and duration of response as well as safety considerations. Patients with refractory acute
leukemias and aggressive lymphomas over the age of 18 are eligible. Donors will be selected amongst family
members. Full HLA typing of patients and donors will occur as will chimerism assessments. 1-2x108 CD3+ cells/
kilogram will be infused on Day 0 without preconditioning. Patients will be monitored for their response to therapy,
in particular for the development of a cytokine release syndrome (CRS) that has been previously described. Blood
samples will be taken at the onset, during, and following the cessation of CRS so as to study effector cells,
cytokine/chemokine release patterns, and extracellular vesicle populations. Initially, six patients will be enrolled on
study to determine safety. Provided the treatment is deemed safe, a total of 25 patients will be enrolled to
determine efficacy.
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Discussion: Cellular Immunotherapy for Refractory Hematological Malignancies provides a novel treatment for
patients with relapsed/refractory acute leukemia or aggressive lymphoma. We believe this therapy offers the
immunological benefit of bone marrow transplantation without the deleterious effects of myeloablative
conditioning regimens and minus the risk of GVHD. Laboratory correlative studies will be performed in conjunction
with the clinical trial to determine the underlying mechanism of action. This provides a true bench to bedside
approach that should serve to further enrich knowledge of host tumor tolerance and mechanisms by which this
may be overcome.
Trial registration: NCT01685606.
Keywords: Acute myeloid leukemia, Immunotherapy, Hematological malignancies, Non-Hodgkin lymphoma,
Cellular therapy, Cytokine release syndromeBackground
Despite recent improvements in the care of patients with
acute myeloid leukemia (AML), the overall prognosis
remains dismal with a 5-year relative survival rate of
slightly over 20% [1]. Typically, AML patients eligible
for curative therapy are treated with high dose chemo-
therapy involving an anthracycline. If remission is
achieved, the majority of patients undergo allogeneic
stem cell transplantation (allo-SCT) for definitive cura-
tive treatment if, based on age and other medical co-
morbidities, they are deemed clinically eligible [2].
Much of the therapeutic effect of stem cell transplant-
ation arises from a graft versus leukemia (GVL) re-
sponse. Unfortunately, GVL is associated with potential
complications such as treatment-related morbidity/mor-
tality from conditioning chemotherapy regimens as well
as graft-versus-host disease (GVHD). Furthermore, even
after complete response and transplantation there is a
30% probability of disease relapse, and patients who ex-
perience a relapse have a 2-year overall survival (OS) of
10-14% [3].
Other hematological malignancies such as acute
lymphocytic leukemia (ALL) employ allo-SCT as up-
front therapy in poor prognostic settings such as
Philadelphia chromosome positive ALL while others,
like aggressive non-Hodgkin lymphoma (NHL), utilize
allo-SCT in cases of relapsed disease. As is the case
in AML, patients with ALL and NHL requiring allo-
SCT have poor 5 year OS of 30-38% [4-6] and 24-27
% [7,8], respectively. Similar to AML, allo-SCT of re-
lapsed ALL and NHL is limited by treatment related
morbidity/mortality [7-9]. Hence, additional thera-
peutic modalities for acute leukemia and aggressive
lymphomas are needed. Herein, we propose an alter-
native mechanism for cell-directed immunotherapy in
relapsed and refractory hematological malignancies
that does not require high-dose chemotherapy for
conditioning. In our protocol, termed cellular im-
munotherapy, the goal of cell infusion is not engraft-
ment but instead is the purposeful rejection of donorcells so as to elicit a complex cytokine storm that, we
believe, breaks host tumor tolerance.
Laboratory origins of cellular immune therapy
The origins of cellular immunotherapy stem from early
work describing engraftment without myeloablation.
Based on the previous work of others, we initially stud-
ied the capacity of murine marrow cells to engraft into
non-irradiated mice [10]. From the experimental data
obtained, we concluded that donor cell engraftment is
not only possible without myeloablation but is also
quantitative in nature by virtue of competition between
host and donor cells [11]. Greater numbers of donor
cells infused results in higher levels of engraftment.
However, in the clinical setting non-myeloablative engraft-
ment is not possible due to the high number of donor cells
that would be required. Therefore, we next examined
levels of syngeneic murine engraftment with minimal
myeloablation. Utilizing small doses of radiation (50-
100 cGy) we demonstrated significant engraftment [12].
The thought behind efficacy in minimal myeloablation
was that small radiation doses were stem cell toxic but not
myelotoxic. Initial attempts by our group to translate
these findings to the allogeneic setting were unsuccessful
secondary to immune barriers. Eventually, however, dur-
able non-myeloablative engraftment was possible through
anti-CD40 ligand antibody co-stimulatory blockade in the
setting of multiple stem cell infusions [13].
Clinical origins of cellular immune therapy
Infusion of HLA identical pheresed cells
The above murine studies became the foundation of a
clinical approach for patients with refractory leukemia
and lymphoma. Initially, we infused graded doses of hu-
man leukocyte antigen (HLA) identical allogeneic T-cells
into eleven minimally myeloablated (100 cGy total body
irradiation) patients with refractory hematological malig-
nancies in an attempt to achieve durable engraftment.
Nine patients achieved mixed or complete chimerism.
Four patients attained a complete response (CR), two of
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single patient treated for refractory AML, in two patients
with NHL and in one patient with multiple myeloma
(MM). Five patients developed significant acute GVHD,
resulting in one death. Of the patients achieving a CR,
three developed 100% chimerism. The fourth patient in
CR had only a transient 5% chimerism for one week but
interestingly had a sustained CR of over 42 months. An-
other patient with chronic lymphocytic leukemia (CLL)
showed a 75% reduction in lymphadenopathy despite no
evidence for chimerism thereby suggesting that the cel-
lular infusion may have activated the patient’s own im-
mune system against their hematologic malignancy. In
the end, we determined the infusion of 1 × 108 T-cells
per kg along with a median of 5 × 104 CD34+ cells per
kg from non-mobilized HLA identical blood was safe, ef-
fective, and warranted further clinical study [14].Infusion of HLA haploidentical pheresed cells
In order to increase the number of patients eligible for
cellular infusion, we next evaluated the infusion of
haploidentical peripheral blood cells into 26 patients with
refractory hematologic malignancies [15]. Granuloctye
colony stimulating factor (G-CSF) mobilization was used
for collection of peripheral blood cells. Following 100 cGy
of total body irradiation (TBI), patients were infused with
escalating levels of CD3+ cells. The study recruited thir-
teen patients with AML, six with NHL, five with MM, one
with ALL and one with chronic myeloid leukemia (CML).
No responses were seen in the eight patients treated
with 1 × 106 or 1 × 107 CD3+ cells per kg. At higher
CD3+ dose levels of 1–2 × 108 per kg, objective re-
sponses were seen in 14 out of 18 patients. Two of six
patients with NHL remained free of disease at 76
months and 82 months, respectively, while two add-
itional NHL patients obtained partial responses (PR).
There were 3 durable CR lasting 8, 11 and 31 months,
respectively, and 7 transient responses in 13 patients
with AML (Table 1). Remarkable, all responses occurred
outside of donor chimerism. Serial bone marrow biop-
sies performed in several patients showed evidence of
large tumor reduction and early resumption of normal
hematopoiesis.
Toxicities included well-tolerated myelotoxicity. An
immediate post-infusion immunologic syndrome, whichTable 1 Summary of responses seen in 26 patients with
refractory hematological malignancies treated with









AML 3/13 (23%) 0/13 (0%) 7/13 (54%) 10/13 (77%)
NHL 2/6 (33%) 2/6 (33%) 0/6 (0%) 4/6 (66%)we termed “haploimmunostorm”, was observed. This
was universally characterized by fever and variably by
skin rash, diarrhea, liver dysfunction, effusions, respira-
tory distress and edema. These signs and symptoms
were variable between patients. It only occurred in pa-
tients infused with at least 1 × 108 CD3+ cells per kg,
began 14 hours after cell infusion, and remitted rapidly
with methylprednisolone, 2 mg/kg/day within 6–8 hours
of the onset of the haploimmunostorm. Typically, we
allowed this syndrome to persist for at least 48 hours as
it was hypothesized that this might be a component of
the therapeutic response.
Donor chimerism, as determined by short tandem re-
peat testing in multiplex battery with 1-5% sensitivity,
was not seen in most patients. Only two patients devel-
oped donor chimerism and both patients died; one pa-
tient clearly died of GVHD and the other possibly from
GVHD. Hence, we were able to document complete re-
sponses, some of which were durable, with cell infusions
in the absence of demonstrable engraftment.
Evaluation of serum cytokine levels during the haplo-
immunostorm revealed elevations of multiple cytokines
including interferon γ which in the murine model has
been shown to play a role in the host versus tumor re-
sponse [16,17]. The pattern of cytokine elevations was
distinct from the patterns seen with the engraftment
syndrome and GVHD. These elevations were felt to be
related to the haploimmunostorm manifestations.
Cytokine release syndrome; other studies
Similar to the description of the haploimmunostorm
phenomenon is a cytokine release syndrome (CRS) that
has been observed in the chimeric antigen receptor
(CAR) modified T-cells studied in CLL patients by the
University of Pennsylvania group [18]. In their work, the
cytokines IFN γ and IL-6 are elevated in patients whose
CLL responds to infusion of modified CAR T-cells while
those patients who exhibit no CRS show no response to
this therapy. These initial findings in CLL have been
reproduced in patients with ALL [19]. The clinical find-
ings of hypotension and hypoxia are also similar to our
experiences with haploimmunostorm, as is the use of
steroids to treat these symptoms. More recently, they
have shown blockade of IL-6 with the monoclonal anti-
body tociluzimab is able to mitigate the side effects of
cytokine release syndrome without dampening the anti-
tumor activity [20].
Nonengraftment haploidentical cellular therapy; other
studies
The clinical efficacy of cellular therapy has been
replicated by Guo and colleagues in a study of pa-
tients ≥ 60 with AML [21]. Here, they randomized
patients to either receive chemotherapy alone or
Reagan et al. Journal of Translational Medicine 2013, 11:150 Page 4 of 9
http://www.translational-medicine.com/content/11/1/150chemotherapy with haploidentical G-CSF mobilized
peripheral blood stem cells (PBSC). In the chemother-
apy alone group, the CR rate was 43% while the CR
rate in the chemotherapy and PBSC group was 80%.
Furthermore, the 2-year progression free survival
(PFS) with chemotherapy alone was 10% in contrast
to a 2-year PFS of 39% in the chemotherapy and PBSC
cohort. These results show clear activity for cellular ther-
apy in patient population with a notoriously dismal prog-
nosis. A subsequent study performed by Guo et al. infused
HLA-mismatched donor G-CSF mobilized PBSC follow-
ing 3 cycles of cytarabine for AML patients who attained
CR after induction chemotherapy. In total, 101 low- and
intermediate-risk AML patients were included in this
study. In the low-risk group, the 6-year leukemia free sur-
vival (LFS) rate was 84% while the OS was 89%. In the
intermediate-risk group the LFS was 59% and the OS was
65% [22]. These are remarkable responses for patients
with AML in whom the average 5-year OS is 55% and
24% in similar risk groups [23]. Interestingly, this same
group reported a benefit of donor cell infusions with
chemotherapy for the treatment of myelodsyplastic syn-
drome compared to chemotherapy alone [24].
Study rationale
The infusion of 1–2 × 108 CD3+ haploidentical cells per
kg into minimally irradiated patients with refractory
lymphoma or leukemia results in dramatic and some-
times durable responses in the absence of engraftment
[15,21,22]. In this setting, the patients developed a
unique CRS characterized by fever, diarrhea, liver func-
tion abnormalities, skin rash and pulmonary symptoms.
This suggests the activity in haploidentical blood cell in-
fusion is likely due to activation of the recipient’s im-
mune system against leukemia/lymphoma and not due
to graft versus tumor. This response may be related to
CRS development as described by our group [15] and
others [18,20].
In order to increase the host immune response to
haploidentical cellular infusion, no pre-infusion irradiation
or chemotherapy will be administered. Furthermore, as G-
CSF would be administered to healthy volunteers the un-
clear benefit of the addition of this cytokine is offset by
the potential side effects such as headache, fever, and bone
pain. Moreover, G-CSF mobilization serves to shift the re-
sponse from a TH1 to TH2 through the increased produc-
tion of T-regulatory cells thereby potential decreasing the
immune response [25]. Therefore, in this study,
haploidentical cells will be collected directly from the
donor and infused into the patient. The end goal is pur-
poseful rejection of donor cells by the host immune sys-
tem which, we postulate, results in breakage of host
tumor tolerance. The underlying mechanism behind this
phenomenon has not been fully elucidated but is thoughtto involve a complex interaction between interferon γ,
CD8+ T-cells, NK cells, and antigen presenting cells. La-
boratory correlative studies to determine the mechanism
of action will be conducted alongside the clinical trial.
Methods/design
The current trial is a single-arm phase I/II non-
randomized study designed to evaluate the safety and ef-
ficacy of haploidentical cellular infusion in patients with
refractory acute leukemia and aggressive lymphoma. Add-
itional laboratory correlative studies will be performed in
conjunction with the clinical trial to determine an under-
lying mechanism of action.
Primary and secondary objectives
The primary objective is to assess the overall response rate
of cellular immune therapy with HLA-haploidentical per-
ipheral blood pheresed cells in patients with relapsed/re-
fractory hematological malignancies.
Secondary objectives will more accurately describe the
clinical effect by assessing the time-to-progression, PFS
and OS for patients with relapsed/refractory hematologic
malignances following HLA-haploidentical cellular ther-
apy. An additional secondary objective is to evaluate the
rate of dose-limiting toxicities of HLA-haploidentical
peripheral blood pheresed cellular infusions.
Exploratory objectives
These objectives will serve to decipher the underlying
process by which cellular therapy results in clinical re-
sponse. We will evaluate in vitro mixed lymphocyte as-
says of donor and recipient cells to determine if in vitro
stimulation and cytolytic activity corresponds to clinical
efficacy. Furthermore, samples will be taken prior to,
during, and after the onset of the cytokine release syn-
drome in order to determine cytokine release profiles, ef-
fector cell populations, and extracellular vesicle release.
Study design
All patients over the age of 18 with relapsed aggressive
lymphoma or acute myeloid/lymphoid leukemia with at
least one prior therapy and no curative options are eli-
gible (Table 2). HLA-haploidentical donors over the age
of 18 whom are healthy and meet criteria of blood dona-
tion are eligible (Table 3).
Selected donors will undergo leukapheresis. The final
product will be analyzed for CD3+ and CD34+ content
via flow cytometry. The product will be administered
unprocessed on day 0 (same day as leukapheresis) with
1–2 × 108 CD3+ cells per kg irrespective of the number
of CD34+. No specific viral or bacterial prophylaxis is
required. The infusion of HLA-haploidentical peripheral
blood cells must be initiated within 8 hours of product col-
lection and completed within 24 hours. Acetaminophen
Table 2 Criteria for recipient (patient) enrollment
Recipient
eligibility criteria
Inclusion Criteria Age ≥ 18
Histologic confirmation of the following leukemias/
lymphomas:
• Mantle cell lymphoma with Ki-67>30%
• Diffuse Large Cell Lymphoma
• Burkitts Lymphoma
• Systemic T Cell Lymphomas
• Acute Myeloid Leukemia
• Acute Lymphoblastic Leukemia
Recurrence or progression of disease after at least 1
prior standard treatment
Progression of disease within 6 months of last
treatment
No available curative treatment option
≥ 4-weeks since prior chemotherapy or radiation
(Exception: Hydroxyurea may be utilized up to 48
hours prior to treatment)
Life expectancy of 2 months at treatment initiation
≥ 6 months post autologous stem cell transplant
DLCO ≥ 40% with no symptomatic pulmonary
disease.
LVEF ≥ 40% by MUGA or echocardiogram.
Creatinine ≤ 2.0 mg/dl, Total bilirubin <1.5x the
upper limit of normal (ULN), AST < 3x ULN
Non-pregnant and willing to use appropriate birth
control during study period
Exclusion criteria Previous allogeneic stem cell transplant
Previous purine analog (fludarabine, pentostatin, 2-
CDA) or alemtuzumab within 1 year of entering the
study
CML, CLL, multiple myeloma, and indolent
lymphoma (follicular lymphoma, marginal zone
lymphoma)
HLA antibodies to donor HLA type
HIV-1 or 2 positive
Oxygen dependant COPD
Failure to demonstrate adequate compliance with
medical therapy and follow-up
Significant medical or psychiatric illness that would
impair the ability to participate in protocol therapy
Active systemic infection
Table 3 Criteria for haploidentical PBSC donation
Donor eligibility
criteria
Inclusion criteria Biological family members
3/6 HLA match (using loci A, B, DR)
18 years of age
No malignancy in the past 5 years except for
non-melanoma skin cancers
Normal CBC
β-HCG urine or serum negative if donor is of
childbearing age
Adequate venous access so leukapheresis can
be performed via standard peripheral IV
Exclusion criteria HIV-1 or 2, syphilis, hepatitis B or C, HTLV 1 or 2,
CMV, Chagas, and West Nile Virus positive
Symptomatic congestive heart failure (CHF)
Oxygen dependant chronic obstructive lung
disease (COPD)
Cirrhosis or active liver disease
History of any lymphoid, myeloid or other
non-solid malignancy
History of transplantation
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istered 30 minutes prior to haploidentical infusion. During
the infusion, patient will be monitored for blood pressure,
temperature and oxygen saturation. This monitoring will
continue for 2 hours after infusion at the following time
points; every 15 minutes the first hour post infusion and
every 30 minutes the second hour post infusion.The infusion will be stopped should the patient de-
velop grade 3 or 4 infusion-related reactions. For grade
2 infusion-related reactions the following protocol will
be followed:
1st occurrence of Grade 2 infusion related reaction
1. Infusion placed on hold
2. Acetaminophen 650 mg PO × 1
3. Diphenhydramine 50 mg IV × 1
4. Ranitidine 50 mg IV ×1
5. Infusion restarted following improvement in
symptoms to Grade 1 or less
2nd occurrence of Grade 2 infusion related reaction
1. Infusion placed on hold
2. Methylprednisolone 100 mg IV × 1
3. Infusion restarted following improvement in
symptoms to Grade 1 or less
Toxicities/Safety
Patients will be monitored for cell infusion syndrome
and cytokine release syndrome. Patients will be given
methylprednisolone for Grade 3 or 4 Toxicities based on
NCI CTC version 4.0 criteria. Furthermore, percent chi-
merism will be assessed using short tandem repeats 2
days post cellular infusion, 14 post cellular infusion, and
every 14 days thereafter as long as chimerism persists
(Figure 1). Lack of chimerism will obviate the risk of
GVHD. After 6 patients have been followed for a




























Figure 1 Schematic depicting key time points for blood sample accrual for translational studies to be incorporated into the Cellular
Therapy Protocol (HLA= Human leukocyte antigen, KIR= Killer-cell immunoglobulin-like receptor, STR= short tandem repeat,
CRS= Cyokine release syndrome).
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University Oncology Research Group (BrUOG) will re-
view safety data prior to reopening accrual. Data from
the safety review will be shared with the FDA.
Adverse events will be scored according to the NCI
CTCAE version 4 criteria. Dose limiting toxicity (DLT)
will be defined as any of the following treatment related
events:
 Grade 3 graft versus host disease lasting > 7 days
 Grade 4 graft versus host disease of any duration
 Grade 3 infusion related symptoms lasting > 7 days
 Grade 4 infusion related symptoms of any duration
In the safety run-in for the first 6 patients, if 2 or less
of 6 patients have a dose limiting toxicity then accrual
will be allowed to extend to a total of 25 patients. If 3 or
more of 6 patients have a DLT, or there is one grade 5
treatment-related adverse events, protocol accrual will
be suspended. If this circumstance occurs, the BrUOG
data safety monitoring group will review the adverse
event data and make appropriate recommendations to
the BrUOG scientific advisory board and the FDA about
the study.
The safety evaluation of all 25 evaluable patients is a
major objective of this study. A 35% rate of treatment-
related adverse events from cellular infusion will be con-
sidered unacceptable.
Response criteria
Criteria for AML and ALL: Includes complete response
(CR), partial response (PR), transient response, treatmentfailure, treatment failure due to patient death, and relapse
[26] (Table 4). Response Criteria for Lymphoma: Includes
CR, PR, stable disease (SD), relapsed disease or progres-
sive disease (PD) [27] (Table 4).
Statistical considerations
As noted above, the safety of cellular therapy administra-
tion in the first six patients will be reviewed by the FDA
and the BrUOG Data Safety Monitoring Board (DSMB).
These reviews will be shared with our institutional IRB.
If the treatment appears safe, as determined by the FDA
and the BrUOG DSMB with institutional IRB agreement,
the protocol may be reopened to treat a total of 25 pa-
tients. A sample size of 25 patients will differentiate be-
tween a 10% level of activity and a 30% level of activity.
Specifically, the hypothesis to be tested is:
H0: p< 0.1 versus H1: p> 0.3
A Simon two-stage design will be used in this study.
The first 15 evaluable patients will be assessed for activ-
ity. The trial will be terminated early if activity is ob-
served in 0 or 1 of these 15 patients, and it will be
concluded that the true activity rate is unlikely to be
> 10%. If activity is demonstrated in at least 2 patients,
accrual will continue until a total of 25 evaluable pa-
tients are enrolled. If activity is observed in 5 or fewer of
25 patients, the null hypothesis will be accepted and it
will be concluded that there is not sufficient activity to
merit further investigation of the regimen. Otherwise, it
will be concluded that the treatment regimen has suffi-
cient activity to warrant further investigation.
Table 4 Response criteria for cellular immunotherapy in both leukemia and lymphoma [26,27]
AML/ALL Lymphoma
Complete Remission (CR) • No leukemic blasts in PB Nodal
• No extramedullary leukemia • If PET positive prior to treatment then any mass provided PET
negative. If PET negative or variably positive then nodal regression
to normal size on CT• BM cellularity > 20% without Auer rods and <5%
blasts
• ANC > 1.0 × 109/L Spleen/Liver
• Platelet count > 100x109/L. • Not palpable, resolution of nodules
Bone Marrow
• Morphological clearance or if morphology equivocal then IHC
normalization
Partial Remission (PR) • All criteria for CR except bone marrow may have
5-20% blasts
Nodal
• ≥ 50% decrease in the SPD of up to 6
• largest masses
Spleen/Liver
• ≥ 50% decrease in SPD of nodules if multiple nodules, ≥ 50% in
size of the transverse diameter of a single nodule if solitary mass
Bone Marrow
• No new bone marrow involvement
Transient Response (TR) • Loss of PB blasts N/A
• >50% reduction in BM blasts
Stable Disease (SD) N/A • If PET positive pretreatment, then PET positive post treatment at
previous sites. If PET negative pretreatment then no CT change in
size of previous lesions.
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This design yields a type I error rate of <0.05 (α=0.03)
and power of 80% when the true response rate is 30%.
Overall survival, time to progression, and progression
free survival will be determined by the Kaplan Meier
method (from the time of study enrollment).
Translational endpoints
Prospective studies for evaluation of donor and patient
alloreactivity
Within our center we have created an in vitro study in
which inactivated randomly selected mismatched donor
cells are mixed with CD3+ cells from leukemia patients.
Stimulated CD3+ patient cells are then placed on 51Cr
labeled leukemic blasts with cytolytic activity measured
by 51Cr release. Preliminary results obtained thus far
show cytolytic anti-leukemic activity in approximately
half of the stimulated patient CD3+ cells [28]. Because
these results are about the same frequency as the re-
sponses to cellular immunotherapy, it raises the question
of whether this in vitro assay would be predictive of
in vivo responses using the donor/patient combination
to be tested. Further, if CD3+ proliferation and cytolytic
activity, as determined by in vitro assays, is donor de-
pendant then it may be possible to identify an optimal
donor. These in-vitro studies will be done in a prospect-
ive manner by obtaining additional tubes of blood frompatient and donor at the day −28 time point (Figure 1).
Blood will also be obtained from other individuals that
could have been considered as donors or from com-
pletely mismatched normal controls.
CD3+ cells from recipient peripheral blood mono-
nuclear cells (PBMC) will be positively isolated using
immunomagnetic particles from Miltenyi Biotec©. Mito-
mycin C treated PBMC from donors (stimulators) will
be placed in a mixed lymphocyte culture (MLC) with
recipient CD3+ cells (responders). CD33/CD34+ cells
from Recipient CD3- fraction will be positively selected
with immunomagnetic particles from Miltenyi Biotec to
create a blast target population for cytolytic studies.
MLC proliferation assays will be measured on day 5. On
day 7, MLC cells will be collected. Recipient CD33/34+
blasts will be labeled with 51Cr MLC stimulated cells will
be co-cultured with 51Cr labeled blasts for cytolytic as-
says. The ability to induce the patient’s CD3+ cells to
generate anti-leukemic effector cells using the different
stimulator cells will be compared to the clinical results
subsequently seen in the patient.
Identification of functional effector cells after cellular
infusion
Blood samples will be taken frequently during the first
few days after cellular infusion (Figure 1). Blood will be
centrifuged with the plasma collected from these
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PBMC will be isolated from the cell pellet using Ficoll-
Hypaque discontinuous centrifugation. An aliquot of
PBMC will be frozen down for killer-cell immunglobulin
like receptor (KIR) expression using Luminex based typ-
ing (Gen-Probe) [29]. PBMC analysis will include cell
staining for the presence of various subpopulations and
their activation status. A panel of anti-HLA antibodies
coupled with AlexaFluor 488 that has been shown to be
useful for detecting microchimerism during pregnancy
in 90% of individuals tested has been made available
[30,31]. These antibodies will be used to distinguish
donor and recipient cells. In addition to determining the
percentage of donor cells circulating in the blood at
these different time points, these antibodies can be com-
bined with antibody staining panels that define different
subpopulations (CD3, CD4, CD8, CD56, CD69), as well
as cytokine and granzyme production by these cells. If
there are sufficient cells, it may be possible to use anti-
body panel staining with anti-HLA antibodies to sort
for donor and/or recipient cells. Once collected, these
populations could be tested directly for their ability to
lyse leukemic target cells or natural killer target cells
such as K562. If there are limited number of cells, PCR
will be performed to determine the expression of loci
expressing effector molecules.
Identification of cytokine, chemokine, and granzyme
profiles and extracellular vesicle release patterns
Cytokine (IL-2, IL-4, IL-6, IL-10, IL-12, IL-15, IL-18,
IL-21, IFN γ), chemokine (MCP, MIP1b, CX3CL1) and
granzyme (A, B) levels present in the plasma will be de-
termined using multiplex assays (CBA flex set assays or
Luminex assays) using the same blood samples obtained
for effector cell analysis (Figure 1). In addition to cyto-
kine profiles, patient plasma samples will be examined
for extracellular vesicle content. Vesicles will be isolated
by ultracentrifugation and examined for protein and
RNA content.
Discussion
Cellular Immunotherapy for Refractory Hematological
Malignancies provides a novel treatment for patients
with relapsed and refractory acute leukemia or aggres-
sive lymphoma. We believe this therapy could offer the
immunological benefit of bone marrow transplantation
(i.e. GVL) without the deleterious effects of myeloablative
conditioning regimens and the risk of GVHD. Although
the exact mechanism of action behind the clinical efficacy
remains to be elucidated, we believe that the potential
therapeutic benefit is too great to ignore. Furthermore, la-
boratory correlative studies will be performed in conjunc-
tion with the clinical trial. This provides a true bench-to
-bedside approach that should serve to further enrichknowledge of host tumor tolerance and mechanisms by
which this may be overcome.
The overriding goal of this phase I/II study is to gener-
ate clinical responses with a treatment that is safe and
well tolerated. The initial six patients enrolled will be re-
evaluated for safety considerations with potential alter-
ations to the protocol made in order to enhance both
safety and efficacy. The purposeful rejection phenomenon
seen within our study could serve as a platform for add-
itional trials of host-mediated immunotherapy for other
malignancies.
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